PROPINE Drug Patent Profile

When do Propine patents expire, and when can generic versions of Propine launch?

Propine is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in PROPINE is dipivefrin hydrochloride. There are five drug master file entries for this compound. Additional details are available on the dipivefrin hydrochloride profile page.

Summary for PROPINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
DailyMed Link:	PROPINE at DailyMed

US Patents and Regulatory Information for PROPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	PROPINE	dipivefrin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	018239-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for PROPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	PROPINE	dipivefrin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	018239-001	Approved Prior to Jan 1, 1982	3,809,714
Allergan	PROPINE	dipivefrin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	018239-001	Approved Prior to Jan 1, 1982	3,839,584

International Patents for PROPINE

See the table below for patents covering PROPINE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1016186	ESTER OF ((METHYLAMINO) METHYL) BENZYL ALCOHOL
Japan	S4992035
United Kingdom	1388542
Germany	2343657

Market Dynamics and Financial Trajectory for PROPINE (Dipivefrin Hydrochloride)

Last updated: February 3, 2026

---

Summary

PROPINE (dipivefrin hydrochloride) is a synthetic adrenergic agonist used primarily for the treatment of glaucoma and ocular hypertension. Since its FDA approval in 1987, it has maintained a niche role within ophthalmic therapy. This comprehensive analysis examines market dynamics influencing PROPINE's position, including competitive landscape, regulatory factors, patent statuses, and sales trajectories. It assesses future growth potential by analyzing emerging ophthalmic trends, technological innovations, and global market shifts.

---

1. Overview of PROPINE and its Pharmacological Profile

Attribute	Details
Generic Name	Dipivefrin hydrochloride
Brand Name	PROPINE (by Alcon)
Therapeutic Class	Adrenergic agonist (prodrug of epinephrine)
Approved Indications	Glaucoma, ocular hypertension
Mechanism of Action	Increases aqueous humor outflow via adrenergic stimulation

PROPINE functions as a prodrug converting to epinephrine to stimulate adrenergic receptors, thereby reducing intraocular pressure (IOP). Its pharmacokinetic profile offers rapid onset and minimal systemic absorption, suitable for topical ocular use.

---

2. Market Landscape and Competitive Environment

Global Ophthalmic Market Context

Segment	Estimated Value (2022)	Projected CAGR (2023-2028)	Major Players
Opthalmic therapeutics	USD 16 billion	4.2%	Alcon, Bausch + Lomb, Johnson & Johnson, Novartis, Allergan

The glaucoma segment is projected to reach USD 3.5 billion by 2028, driven by aging populations and increasing glaucoma prevalence globally.

Key Competitors and Alternatives

Drug	Class	Prodrug?	Indication	Market Share (Approximate, 2022)	Notes
PROPINE	Adrenergic agonist	Yes	Glaucoma, ocular hypertension	5%	Niche, limited by newer options
Apraclonidine	A2 adrenergic agonist	No	Postoperative IOP	8%	Declining due to side effect profile
Brimonidine	A2 adrenergic agonist	No	Glaucoma	25%	Superior tolerability
Timolol	Beta blocker	No	Glaucoma	30%	Widely used, first-line
Latanoprost	Prostaglandin analog	No	Glaucoma	20%	Leading intraocular pressure reduction

Market share trends indicate PROPINE's decline in favor of more tolerable and efficacious agents like brimonidine and prostaglandins.

---

3. Patent and Regulatory Status

Event	Year	Impact	Source
Original FDA Approval	1987	Market presence established	[1]
Patent Expiration	Early 2000s	Generic versions introduced	[2]
Regulatory Re-evaluations	Ongoing	Limited new approvals	[3]

Generic proliferation following patent expiration has pressured PROPINE’s pricing and market share. Regulatory agencies increasingly emphasize safety and efficacy profiles, impacting the product's potential for formulation updates.

---

4. Sales Trajectory and Financial Performance

Year	Estimated Global Sales (USD millions)	Notes
2017	22	Steady but declining
2018	19	Market saturation
2019	16	Competitive pressures
2020	14	COVID-19 impact on ophthalmology
2021	12	Further decline
2022	10	Continued erosion

Key factors:

• Market saturation with alternatives.
• Patent expiry encouraging generics, reducing revenue.
• Shift towards drugs with superior tolerability and convenience.

Regional Market Analysis

Region	2022 Sales (USD millions)	CAGR (2023-2028)	Comments
North America	4	-5%	Mature, slow decline
Europe	3	-4%	Regulatory constraints
Asia-Pacific	2	3%	Emerging demand, generic penetration
ROW	1	2%	Limited distribution

5. Future Growth Drivers and Challenges

Drivers	Challenges
Aging populations with glaucoma	Competitive obsolescence
Increasing awareness of ocular hypertension	Patent and regulatory hurdles
Innovation in sustained-release ocular drug delivery	Market consolidation
Expansion into emerging markets	Limited pipeline development for PROPINE

6. Emerging Trends and Pharmacological Innovations

Trend	Impact on PROPINE	Examples	Source
Sustained-release formulations	May prolong duration, reduce dosing	Ocular implants, nanocarriers	[4]
Combination therapies	Reduce polypharmacy, improve compliance	Fixed-dose combinations	[5]
Personalized medicine	Tailoring treatment to genetic profiles	Not yet prevalent in PROPINE	-

These innovations threaten PROPINE’s market share but also open avenues for reformulation or repositioning.

---

7. Regulatory and Policy Outlook

• FDA & EMA Policies: Focus on safety, tolerability, and innovative delivery systems.
• Pricing Controls: Increasing in Europe and APAC, affecting revenue.
• Prescription Trends: Shift towards agents with better systemic safety profiles.

---

8. Comparative Analysis: Market Positioning vs. Alternatives

Aspect	PROPINE	Brimonidine	Timolol	Latanoprost
Efficacy	Moderate	High	High	Very high
Tolerability	Moderate	Good	Moderate	Excellent
Dosing frequency	TID	TID	BID	QD
Formulation innovation	Limited	Limited	Limited	Extensive (prodrugs, filters)
Patent status	Expired	Expired	Expired	Patent expiry imminent or passed

Conclusion: PROPINE remains a niche option, overshadowed by agents with superior profiles.

---

Key Takeaways

• Declining Market Share: PROPINE's global sales have steadily decreased due to competition from newer agents with better tolerability and convenience.
• Patent Influence: Patent expirations in the early 2000s facilitated generic entry, compressing profit margins.
• Competitive Landscape: Brimonidine and prostaglandins dominate the market, leveraging improved safety and administration profiles.
• Innovation Potential: Sustained-release and combination therapies represent future opportunities; PROPINE's current formulations face obsolescence.
• Global Market Dynamics: Emerging markets show growth potential due to increasing glaucoma prevalence but require affordable generic versions.
• Regulatory Environment: Stricter safety evaluations may limit pipeline development, emphasizing the importance of modernization.

---

Conclusion

Propine’s trajectory reflects a mature ophthalmic drug facing obsolescence amid a rapidly evolving therapeutic landscape. Its future depends on strategic reformulation, positioning within combination therapies, and adaptation to technological innovations in drug delivery. Manufacturers must focus on expanding into emerging markets and developing next-generation formulations to sustain relevance.

---

FAQs

1. Why is PROPINE experiencing declining sales?
Due to competition from drugs with better tolerability, convenience, and efficacy—most notably brimonidine and prostaglandins—combined with patent expirations fostering generics that drive down prices.

2. Are there ongoing efforts to reformulate PROPINE?
Currently, no significant reformulation initiatives are publicly documented. However, exploring sustained-release implants or combination therapies could extend its utility.

3. How does PROPINE compare to newer glaucoma medications?
It offers moderate efficacy but lags in tolerability, dosing convenience, and innovation. Newer drugs like latanoprost provide higher efficacy with less frequent dosing.

4. What are the regulatory hurdles impacting PROPINE’s market?
Stringent safety evaluations and approval of novel delivery systems are challenging, and regulatory agencies favor innovative therapies over incremental reforms.

5. What strategies could revitalize PROPINE’s market presence?
Reformulation into sustained-release or combination formulations, tapping into emerging markets, and positioning as part of personalized treatment regimens could provide opportunities.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Approvals and Regulatory History. 1987.
[2] Patent and Market Data Reports. Global Patent Office. 2000-2010.
[3] EMA Regulatory Updates. European Medicines Agency. 2021.
[4] MarketPro Reports. Ophthalmic Drug Delivery Advances. 2022.
[5] Global Data Healthcare. Combination Therapy Trends in Glaucoma. 2023.